Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Bernhard Hemmer, Yael Hacohen et al.|The Lancet Neurology|2021Cited by 518
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple SclerosisCarmen Tur, Xavier Montalbán, Pere Carbonell‐Mirabent et al.|JAMA Neurology|2022Cited by 278
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel Whittam, Brigitte Wildemann, Álvaro Cobo‐Calvo et al.|Multiple Sclerosis and Related Disorders|2020Cited by 179
Neuromyelitis optica spectrum disordersMaría Sepúlveda, Inmaculada Puertas, Thaís Armangué et al.|Neurology Neuroimmunology & Neuroinflammation|2016Cited by 153
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological responseAna Zabalza, Xavier Montalbán, Simón Cárdenas‐Robledo et al.|European Journal of Neurology|2020Cited by 138